Please use this identifier to cite or link to this item:
Title: Non-Hodgkin Lymphoma after treatment with Extended dosing temozolomide and radiotherapy for a glioblastoma: A case report
Authors: Van Ginderachter, Laura
Cox, Tony
Drijkoningen, Ria
Joosens, Eric
Maes, Annelies
Theunissen, Koen
MEBIS, Jeroen 
Issue Date: 2013
Source: Case Report Oncology, 6, p. 45-49
Abstract: Temozolomide (TMZ) is an alkylating agent, used for the treatment of high-grade gliomas. This case report describes the development of a non-Hodgkin lymphoma in a patient treated with extended-dose temozolomide and radiotherapy. In addition to the possible mutagenic effect of temozolomide – as described for all alkylating agents – there might have been an immunosuppressive effect of TMZ. The pathological appearance of the lymphoma as well as the presence of a grade 3 lymphopenia early in treatment supports this hypothesis. As the use of TMZ increases, the awareness that TMZ may induce secondary malignancies should increase as well.
Document URI:
ISSN: 1662-6575
DOI: 10.1159/000346614
Category: A2
Type: Journal Contribution
Appears in Collections:Research publications

Show full item record


checked on Sep 7, 2020

Page view(s)

checked on May 24, 2022

Google ScholarTM



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.